Switching eligible patients from warfarin to Xarelto®1

Switching from a VKA to Xarelto can be straightforward, with no requirement for ongoing monitoring of coagulation parameters during treatment with Xarelto†,1

Xarelto is to be used with caution in patients with CrCl 15–29 ml/min. Use is not recommended in patients with CrCl <15 ml/min.1
Xarelto should be used with caution in patients with renal impairment concomitantly receiving other medicinal products which
increase rivaroxaban plasma concentrations.1